Triptorelin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Triptorelin: From GnRH Agonist Therapy to Hypertrichosis
One-Sentence Summary
Triptorelin is a GnRH (gonadotropin-releasing hormone) agonist, pharmacologically used to suppress the pituitary-gonadal axis in hormone-dependent conditions. The TxGNN model predicts it may be effective for Hypertrichosis (excessive hair growth), but this direction is currently supported by only 1 case report and no clinical trials, and that single report does not actually demonstrate a treatment effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Danish regulatory data (drug not marketed in Denmark); generally known as a GnRH agonist used in hormone-dependent conditions |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.9970% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, triptorelin belongs to the class of GnRH (LHRH) agonists, which, with continuous use, downregulate pituitary GnRH receptors and suppress gonadotropin (LH/FSH) release, thereby reducing gonadal steroid (testosterone) production.
The theoretical rationale for exploring triptorelin in hypertrichosis is that androgen-driven hair growth could, in principle, be reduced by suppressing testosterone. However, the only supporting literature identified (PMID 41822646) does not actually demonstrate this effect: it describes a transgender woman on testosterone-blocking therapy (including triptorelin) who nonetheless developed generalised hypertrichosis — but the cause was attributed to ciclosporin, not to a failure or benefit of triptorelin itself. The case illustrates that androgen suppression does not reliably prevent hypertrichosis from other drug causes, which is the opposite of evidence supporting triptorelin as a treatment.
In short, the mechanistic hypothesis is biologically plausible, but the only available real-world evidence does not support it, and may even argue against a clinically meaningful effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41822646 | 2026 | Case Report | Cureus | A transgender woman on testosterone-blocking therapy (including triptorelin) developed generalised hypertrichosis after starting ciclosporin — illustrating that androgen suppression did not prevent ciclosporin-induced hair growth. Not evidence of a therapeutic effect of triptorelin on hypertrichosis. |
Denmark Market Information
No marketing authorisations are currently registered for triptorelin in Denmark (market status: Not marketed; 0 licences on file).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only available evidence (a single case report) does not support — and arguably contradicts — the hypothesis that triptorelin is effective for hypertrichosis. There are no clinical trials, the drug is not marketed in Denmark, and core safety/label data (TFDA/SmPC warnings, contraindications) and mechanism-of-action data are both flagged as data gaps (one of them blocking).
To proceed, the following is needed:
- Official product label / SmPC data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action documentation
- Dedicated clinical or mechanistic studies evaluating triptorelin specifically for hypertrichosis (the current literature basis does not support the indication)
- Reassessment of Danish market/regulatory pathway, given the drug is not currently marketed in Denmark
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.